Psychedelic Therapy in Austria: Every Legal Route in 2026

If you are considering psychedelic-assisted treatment in Austria — for yourself or for someone close to you — the picture in July 2026 is defined less by what is legal than by who pays. Esketamine is authorized and genuinely available, but public funding runs through hospital stays and case-by-case approvals rather than a routine outpatient entitlement, which is why Vienna has grown a private market of specialist practices. Psilocybin and MDMA remain research-only. This guide covers who qualifies for each route, how to start, what it costs, and what to realistically expect; you can begin orienting yourself with our eligibility check.

At a glance

Esketamine (Spravato): authorized, but the funding runs through the hospital

Spravato is EMA-authorized for treatment-resistant depression — adults whose current moderate-to-severe episode has not responded to at least two antidepressants — taken together with an SSRI or SNRI, and administered under direct clinical supervision with post-dose observation. What Austria has not done is place it in the routine outpatient reimbursement code, so access follows two funding logics:

• Inpatient: if you are treated on a psychiatric ward, esketamine is funded like the rest of your care through the hospital financing system (LKF). The hospital's own psychiatric team is the gatekeeper: it assesses your treatment history and decides whether esketamine belongs in your plan. The treatment-resistant depression outpatient service at AKH Wien, the university hospital of the Medical University of Vienna, is the best-known specialist port of call — its clinicians run one of Europe's most active research groups on fast-acting antidepressants (MedUni Wien).
• Outpatient: outside hospital walls, whether your sickness fund pays is decided case by case by the fund's chief physician (chefärztliche Bewilligung). Your psychiatrist submits the request; the file that decides it is your documented treatment history — substance, dose, duration and outcome for every antidepressant tried in the current episode. Approvals are real but not guaranteed, which is why many Austrian patients end up paying privately.

How to start. Ask your GP or psychiatrist for a referral to a hospital psychiatric service (in Vienna, the AKH treatment-resistant depression service) or have your psychiatrist file the chief-physician request directly. Either way, assemble the written treatment history first — it does more work than anything you say in the room. For how Austria's arrangement compares with its neighbours, see our Europe-wide reimbursement map.

Private practices: the Vienna market

Austria's Wahlarzt system — private physicians whose invoices the sickness funds partly refund — has produced a small but genuine private market for esketamine treatment, concentrated in Vienna. Two practices publish their programs and fees, and both appear in our directory for Austria:

• Ordination Dr. Buchmayer (LEBEN PSYCHE Zentrum, 1090 Vienna) focuses on depression and treatment-resistant depression, offering esketamine as both Spravato nasal spray and infusion in the practice, alongside TMS, tDCS, pharmacogenetics and psychotherapy. Treatment follows a structured course: an induction phase of about eight sessions over four weeks with a formal evaluation, then a maintenance phase over several months. Per the practice's published fee overview, a first consultation is EUR 400 and an esketamine session EUR 150–250, with the two-hour supervised session format required for this medicine.
• PsyTherapie — Dr. Platz (Vienna and Klagenfurt) offers esketamine-based treatment for treatment-resistant depression, OCD, PTSD and chronic suicidal distress, with the option of combining the supervised session with integrated psychotherapy. Published fees are EUR 350 for a treatment session and EUR 450 with psychotherapy; as a Wahlarzt practice of all public insurers, a typical refund of EUR 80–110 per session applies.

How to start and what to check. You can self-refer; expect a psychiatric and medical screening across the first appointments before any treatment decision. Before starting, ask for a written per-session and per-course cost breakdown, ask exactly what your sickness fund will refund, and submit the Wahlarzt invoices — the partial refund is a legal entitlement, not a favour. Off-label ketamine formats beyond the authorized nasal spray should come with a clear medical rationale, supervision and monitoring; a practice that offers the medicine without structured screening and follow-up is a warning sign.

Psilocybin and MDMA: research only

Psilocybin, psilocin, MDMA and the other classic psychedelics are controlled under Austria's narcotic-substances law, the Suchtmittelgesetz, with the substances listed in the annexes of the implementing regulation (Anlage V). There is no medical-access, compassionate-use or reimbursement route for either substance — the national compassionate-use list contains no psychedelic program — and anyone offering psilocybin or MDMA therapy commercially in Austria is operating illegally.

What Austria does have is research. The Medical University of Vienna is recruiting for a psilocybin study in people with depression and anhedonia (NCT07490353): an early-phase, imaging-heavy study of how psilocybin affects the capacity to feel pleasure, run at the university's Department of Psychiatry and Psychotherapy. Be clear-eyed about what that is — a mechanistic study with two supervised sessions and extensive MRI work, not a treatment program — but participation is free, legal and carefully screened. No Austrian MDMA trial is recruiting as of July 2026. If MDMA-assisted therapy matters to you, the realistic options are watching the registries or considering trial sites elsewhere in Europe — our trials guide explains how.

Clinical trials in Austria

The research route is stronger than the country's size suggests: Blossom tracks 14 trials connected to Austria, five of them active (country report). Recruiting studies include:

• The Vienna psilocybin and anhedonia study above (NCT07490353) at the Medical University of Vienna.
• INTENSIFY MDD (NCT05973851), a European Phase 3 study of early-intensified treatment — a second-line antidepressant plus esketamine or ketamine — versus treatment as usual after a first failed antidepressant, with an Austrian site at the Medical University of Innsbruck.
• Ketamine studies at the Medical University of Vienna's fast-acting antidepressant group, including work in obsessive-compulsive disorder.

Participation is free and legal, but screening is strict and enrolment is never guaranteed. See the trials guide for how phases, placebo and consent work, browse trial sites in Austria, and search ClinicalTrials.gov for current listings.

What to expect in treatment

Whichever route you take, the shape of care is similar. It begins with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled.

On a Spravato day — in a hospital service or a private practice — you self-administer the nasal spray under supervision, then stay for an observation period of roughly two hours while staff monitor blood pressure, heart rate and how you feel; a detached, dreamlike sensation and a temporary rise in blood pressure are expected effects that settle as the drug clears. You must not drive for the rest of the day, so arrange a ride home. Induction sessions are more frequent at first — the Vienna practices run roughly twice-weekly sessions in the first month — and then taper based on measured response, alongside a continuing oral antidepressant.

A ketamine infusion, where offered, runs intravenously over about 40–60 minutes with the same monitoring and a recovery period afterwards. In every setting the medicine is one part of the plan: screening, monitoring and follow-up are what make it safe, and psychotherapy or structured integration — which the Vienna practices offer as an explicit add-on — is what helps the effect last.

Risks and who should not start

These treatments are generally well tolerated under supervision, but they are not for everyone, which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation, nausea, dizziness and a short-lived rise in blood pressure and heart rate. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:

• Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease, because of the temporary rise in blood pressure.
• A personal or family history of psychosis or bipolar disorder — a particular caution for classic psychedelics such as psilocybin, which the Vienna study screens for explicitly.
• Severe liver disease or other serious somatic illness.
• Pregnancy or breastfeeding.
• Substance-use concerns, particularly patterns of compulsive use; providers also assess acute suicide risk before and during treatment.

A responsible provider screens for all of these before the first session. If a practice is willing to treat you without that assessment, treat it as a warning sign. To see who is listed near you, browse providers in Austria.

Frequently asked questions

Does Austrian public insurance pay for Spravato?

Sometimes, and the setting decides. As an inpatient, esketamine is funded within the hospital stay through LKF financing. As an outpatient, your sickness fund covers it only with a case-by-case chefärztliche Bewilligung; without one, you pay privately. There is no routine outpatient entitlement.

What is a chefärztliche Bewilligung and how do I get one?

It is the sickness fund's chief-physician approval for a treatment outside routine coverage. Your psychiatrist files it, and it stands or falls on your documented treatment history — every antidepressant tried in the current episode, with dose, duration and outcome. Ask your psychiatrist to submit it before you commit to self-pay.

How much does private esketamine treatment cost in Vienna?

Per the practices' published fee schedules: at Dr. Buchmayer's practice, a first consultation is EUR 400 and an esketamine session EUR 150–250; at PsyTherapie, a session is EUR 350, or EUR 450 combined with psychotherapy. A full induction course means several sessions over about a month, so ask for a per-course total in writing.

Will my sickness fund refund part of a private (Wahlarzt) bill?

Yes — that is how the Wahlarzt system works. PsyTherapie, for example, indicates a typical refund of EUR 80–110 per session. Submit every invoice to your fund, and ask the practice which items are refundable before treatment starts.

Is psilocybin therapy legal in Austria?

No. Psilocybin is controlled under the Suchtmittelgesetz, and the only legal contact with it is inside an authorized study — currently the Medical University of Vienna's trial in depression with anhedonia. Anyone selling psilocybin therapy in Austria is acting illegally.

Can I get MDMA-assisted therapy in Austria?

Not outside research, and no Austrian MDMA trial is recruiting as of July 2026. The realistic options are watching the registries for new studies or considering trial sites elsewhere in Europe.

Sources

1. Blossom: Austria country report
2. Blossom: Medical access in Austria
3. Psychedelic Alpha: Worldwide psychedelic laws tracker
4. Psychedelic Alpha: Beyond Clinical Trials — psychedelic-assisted therapy in Europe's real world (01/2026)
5. EMA: Spravato (esketamine) EPAR
6. Suchtgiftverordnung, Anlage V — controlled psychotropic substances (Austria)
7. Medical University of Vienna — fast-acting antidepressants research group
8. ClinicalTrials.gov: NCT07490353 — psilocybin and anhedonia in depression (Medical University of Vienna; recruiting)
9. ClinicalTrials.gov: NCT05973851 — INTENSIFY MDD (Austrian site: Medical University of Innsbruck)
10. Ordination Dr. Buchmayer, Vienna — services and fee overview
11. PsyTherapie — Dr. Platz, Vienna and Klagenfurt: services and fee schedule
12. Gesundheit Österreich / PPRI — pharmaceutical pricing and reimbursement in Austria (2024)

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Funding decisions in Austria are made case by case, and practice fees change; always verify current costs and coverage with the practice, your sickness fund, or a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.

This guide awaits review by a licensed medical professional.